CD276 and posterior cortical atrophy: As a result, B7-H3 seems to be an attractive target for PCa immunotherapy, and various B7-H3 targeting therapeutics have been studied in pre-clinical and clinical trials and have demonstrated their feasibility for clinical application [14, 38–41].